Table 1.
Patients’ characteristics between the training set and the validation set
| Patient characteristic | Training set | Validation set | P value |
|---|---|---|---|
| Total number | 171 | 199 | |
| Period | 2000–2008 | 2004–2009 | |
| Age at BM | |||
| Median years (range) | 47 (26–87) | 49 (26–80) | .332 |
| ≥70 y | 5 (2.9%) | 8 (4.0%) | .778 |
| <70 y | 166 (97.1%) | 191 (96.0%) | |
| Performance status | |||
| KPS 70–100 | 116 (67.8%) | 116 (58.3%) | .067 |
| KPS <70 | 55 (32.2%) | 83 (41.7%) | |
| Subtype of tumor | |||
| ER+ and/or PgR+/HER2− | 39 (22.8%) | 58 (29.1%) | .865 |
| ER+ and/or PgR+/HER2+ | 38 (22.2%) | 42 (21.1%) | |
| ER− and/or PgR−/HER2+ | 39 (22.8%) | 39 (19.6%) | |
| ER−/PgR−/HER2− | 55 (32.2%) | 60 (30.2%) | |
| Extracranial systemic control at BM | |||
| Controlled (CR, PR, or SD) | 58 (33.9%) | 61 (30.7%) | .506 |
| Progression | 113 (66.1%) | 138 (69.3%) | |
| Anti-HER2 treatment for metastatic BC before BM among HER2+ patients | 50/77 (64.9%) | 55/81 (67.9%) | .738 |
| Overall survival from BM (BM-OS) | |||
| Median months (range) | 9.6 (0.1–88.3) | 7.8 (0.1–57.8) | .069 |
Abbreviations: BM, brain metastasis; KPS, Karnofsky performance status.